# Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies

> **NCT00536978** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 22 (actual)

## Conditions studied

- Lymphoma
- Leukemia

## Interventions

- **DRUG:** ARA-C
- **DRUG:** BCNU
- **DRUG:** Campath-1H
- **DRUG:** Cyclophosphamide
- **DRUG:** Etoposide
- **DRUG:** Fludarabine
- **DRUG:** Melphalan
- **DRUG:** Rituximab
- **OTHER:** Allogeneic Stem Cell Transplantation
- **RADIATION:** Total body radiation (TBI)
- **DRUG:** Methotrexate
- **DRUG:** Tacrolimus
- **PROCEDURE:** Adback NK or T Cell

## Key facts

- **NCT ID:** NCT00536978
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2020-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00536978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00536978, "Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00536978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*